Media stories about Revance Therapeutics (NASDAQ:RVNC) have trended somewhat positive on Friday, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Revance Therapeutics earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 45.4148114053088 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
RVNC has been the topic of several research reports. Cantor Fitzgerald set a $50.00 price target on Revance Therapeutics and gave the company a “buy” rating in a report on Wednesday, November 29th. Mizuho initiated coverage on Revance Therapeutics in a report on Thursday, November 16th. They issued a “buy” rating and a $37.00 price target on the stock. Piper Jaffray Companies upped their price target on Revance Therapeutics from $28.00 to $51.00 and gave the company an “overweight” rating in a report on Tuesday, December 5th. Barclays set a $40.00 price target on Revance Therapeutics and gave the company a “buy” rating in a report on Tuesday, December 19th. Finally, ValuEngine cut Revance Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, December 4th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the company. Revance Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $44.30.
Revance Therapeutics (NASDAQ:RVNC) opened at $33.13 on Friday. Revance Therapeutics has a 52-week low of $18.00 and a 52-week high of $37.45. The firm has a market cap of $1,030.00, a P/E ratio of -8.70 and a beta of 1.62.
In other Revance Therapeutics news, CEO L Daniel Browne sold 7,600 shares of Revance Therapeutics stock in a transaction that occurred on Wednesday, November 22nd. The shares were sold at an average price of $24.94, for a total transaction of $189,544.00. Following the transaction, the chief executive officer now directly owns 133,188 shares in the company, valued at approximately $3,321,708.72. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Mark J. Foley acquired 20,000 shares of the stock in a transaction on Tuesday, November 7th. The shares were purchased at an average price of $26.96 per share, for a total transaction of $539,200.00. Following the completion of the transaction, the director now owns 6,000 shares in the company, valued at approximately $161,760. The disclosure for this purchase can be found here. Insiders own 18.86% of the company’s stock.
Revance Therapeutics Company Profile
Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.